The FDA approved a fast review of  a new Melanoma drug used in a clinical trial at 125 U.S. cancer centers. The study, published in the New England Journal of Medicine on Aug. 19, shows about 23 percent of the patients given ipilimumab are alive two years later, compared with 14 percent of those who did not receive the drug. Those taking ipilimumab lived a median of about 10 months, compared with 6.4 months for those …